Stock Alert: Trinity (TRIB) Down 5.30% in Pre-Market Trading for June 23

Equities Staff  |

Trinity Biotech Plc - ADR (NASDAQ:TRIB) is active in pre-market trading today, June 23, with shares losing 5.30% from the last closing price.

The stock is down 7.69% year-to-date and posted 7.32% gains over the last 5 days.

For technical charts, analysis, and more on Trinity visit the company profile.

Pre-market prices and movements as of 07:17:43 est.

About Trinity Biotech Plc - ADR

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

To get more information on Trinity Biotech Plc - ADR and to follow the company's latest updates, you can visit the company's profile page here: Trinity Biotech Plc - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content